ARDS Landmark Studies
A curated timeline of major trials and practice-changing evidence in Acute Respiratory Distress Syndrome.
Filters
Showing 11 of 11 studiesLower tidal volume ventilation (6 mL/kg) reduced mortality from 39.8% to 31.0% compared to traditional volumes.
Higher PEEP did not reduce mortality compared to lower PEEP when using low tidal volume ventilation.
Conservative fluid management improved oxygenation and reduced ventilator days without affecting mortality.
HFOV increased mortality compared to conventional ventilation. Trial stopped early for harm.
Early neuromuscular blockade improved 90-day survival and increased ventilator-free days in severe ARDS.
Prone positioning reduced 28-day mortality from 32.8% to 16.0% in severe ARDS patients.
Lung recruitment with PEEP titration increased mortality compared to low PEEP. Aggressive recruitment not recommended.
No mortality benefit from early neuromuscular blockade, contradicting earlier ACURASYS findings.
ECMO did not significantly reduce 60-day mortality, but may benefit patients with refractory hypoxemia.
Dexamethasone reduced 28-day mortality in patients requiring respiratory support. Became standard of care.
No significant difference in mortality between early (≤14 days) vs late (>14 days) initiation of 2 mg/kg methylprednisolone in ARDS. Late initiation may be associated with more complications.